Clinical Trials · NCT04969939
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 120
- Start date
- Jul 2021
- Locations
- 25 sites, United States
- Primary endpoint
- Part 1: Number of Treatment-emergent Adverse Events (TEAEs)